ArticleVaccines2022

Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial.

Mine Durusu Tanriover et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.